Valbiotis SA

Chart & performance

D1W1MN

P/E

—

P/S

24.35

EPS

—

Vol. 1Y

83.83%

Shs. 5Y

—

Rev. 5Y

6.07%

Div Yld LY

—

Div Yld TTM

—

Revenues

905k

Net income

-9m

CFO

-8m

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.

URL

https://www.valbiotis.com/

IPO date

Jun 07, 2017

Employees

Domiciled in

Incorporated in

Headquarters & legal address

4 AVENUE ERIC TABARLY
PERIGNY 17180
FR

Trading name

VALBIOTIS HEALTHCARE

Valuation

Latest on right Latest on left

Title EUR in thousands, except ratios and share amounts	FY
Title EUR in thousands, except ratios and share amounts	2025‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT